Article content

VRTX chart

Vertex Pharmaceuticals FDA Approved SYMDEKO

Vertex Pharmaceuticals announced that the FDA approved SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor. SYMDEKO is Vertex’s third medicine approved to treat the underlying cause of CF.

Vertex chart looks like a good swing long setup.

VRTX chart

Good looking lower shadows over last few days as downward momentum in the stock fades. The large players volume and Twiggs Money Flow is not as strong as we would like, but both are still positive.

Vertex also has an upcoming PDUFA on the 28th for Tezacaftor as seen here:

Make money swing trading without being chained to your computer. Join today! Jason Bond Picks

Sofi AI Market Sentiment Gauge

SOFI artificial intelligence market gauge

Picture of SOFI artificial intelligence

Market is overbought.

Leave a Reply